Showing 851-860 of 1046 results for "".
- Neuro-Optometric Rehabilitation Association (NORA) Launches Redesigned Website; Accepts Award Nominationshttps://modernod.com/news/neuro-optometric-rehabilitation-association-nora-launches-redesigned-website-accepts-award-nominations/2480061/The Neuro-Optometric Rehabilitation Association, International (NORA) announced the launch of its redesigned website and new domain name, www.noravisionrehab.org, dedicated to educating patients, caregivers, and health care professionals about neurolog
- NEI: Extremely Rare Gene Variants Point to a Potential Cause of AMDhttps://modernod.com/news/nei-extremely-rare-gene-variants-point-to-a-potential-cause-of-amd/2481519/A study from the National Eye Institute (NEI) identified rare genetic variants that could point to one of the general mechanisms driving age-related macular degeneration (AMD). The variants generate malformed proteins that alter the stability of the membrane attack complex (MAC), which may drive
- Oyster Point's Tyrvaya To Be Covered By the Largest Medicare Pharmacy Benefit Managerhttps://modernod.com/news/oyster-point-pharma-announces-tyrvana-to-be-covered-by-the-largest-medicare-pharmacy-benefit-manager/2481032/Oyster Point Pharma announced that the largest Medicare Pharmacy Benefit Manager in the United States will add Tyrvaya Nasal Spray on its Medicare Part D formularies, effective September 1, 2022. “We are excited to announce this important milestone which will further expand p
- Oyster Point Pharma Announces Restructuring Plan to Reduce Costshttps://modernod.com/news/oyster-point-pharma-announces-operating-expense-streamlining-plan/2480938/Oyster Point Pharma announced it will implement an operating expense streamlining plan that will include a reduction of employee and non-employee expenses across the organization. The company plans to continue to drive the launch of Tyrvaya with approximately 150-200 fie
- Oyster Point Pharma to Present New Analyses at ARVO 2022https://modernod.com/news/oyster-point-pharma-to-present-new-analyses-at-arvo-2022/2480807/Oyster Point Pharma announced the presentation of data analyses at the Association for Research in Vision and Ophthalmology (ARVO) 2022, being held on May 1-4. “We are pleased to be presenting new analyses of the pivotal trial data of Tyrvaya&n
- Oyster Point Pharma Names Donald Santel as Chairman of the Board of Directorshttps://modernod.com/news/oyster-point-pharma-names-donald-santel-as-chairman-of-the-board-of-directors/2479427/Oyster Point Pharma announced the appointment of Donald Santel as non-executive Chairperson and a Director of the company and a member of the Compensation Committee. Mr. Santel joined the Board on July 30, 2021, and will take over as Chairperson as Ali Behbahani, MD, steps down as Ch
- Oyster Point Pharma Announces Pricing of Initial Public Offeringhttps://modernod.com/news/oyster-point-pharma-announces-pricing-of-initial-public-offering/2477064/Oyster Point Pharma announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $16.00 per share. The shares began trading on The Nasdaq Global Select Market on October 31, 2019 under the symbol “OYST.” All of the shares ar
- New CPT Code for Automated Point-of-Care Retinal Imaginghttps://modernod.com/news/new-cpt-code-for-automated-point-of-care-retinal-imaging/2476690/Artificial intelligence diagnostics company IDx announced that the American Medical Association (AMA) has accepted a new category 1 CPT code for automated point-of-care retinal imaging. This new code, submitted by the American Academy of Ophthalmology (AAO) with the support of IDx, facilitates co
- EyeQue Announces Availability of PDCheck on Kickstarter Websitehttps://modernod.com/news/eyeque-announces-availability-of-pdcheck-on-kickstarter-website/2476210/EyeQue, which develops at-home vision tests for smartphones, said this week that its PDCheck tool, a method for measuring pupillary distance (PD), is now available on Kickstarter, according to a
- Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Eye Care Divisionhttps://modernod.com/news/viatris-closes-acquisitions-of-oyster-point-pharma-and-famy-life-sciences-establishing-new-viatris-eye-care-division-1/2481326/Viatris announced that it has closed its acquisitions of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division. The transaction was first announced on November 7. Former Oyster Point Pharma CEO, Jeffrey Nau, PhD, MMS, will lead the new di